Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile
Background: Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein. Aim: To evaluate the clinical characteristics, management and results of treatment of patients with WM at a public...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2019
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300275 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872019000300275 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720190003002752019-07-17Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, ChileCardemil,DanielaLeón,PilarPeña,CamilaValladares,XimenaCabrera,María Elena Prognosis Treatment Outcome Waldenström Macroglobulinemia Background: Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein. Aim: To evaluate the clinical characteristics, management and results of treatment of patients with WM at a public hospital in Chile. Patients and Methods: Review of medical records of 31 patients aged 43 to 85 years (16 males) with WM diagnosed between 2002 and 2017. Clinical features and survival were recorded. Results: All patients had bone marrow compromise, and 31%, extranodal involvement. According to the International Prognostic Score System for WM (IPSSWM) 16, 58 and 26% were at low, intermediate and high risk, respectively. Twenty-five patients (81%) were treated, 32% with plasmapheresis and 36% with rituximab. Four cases (16%) achieved complete remission. Median follow up was 35 months (range 6-159). Estimated overall survival (OS) at 5 and 10 years was 74% and 53%, respectively. According to IPSSWM, the estimated five-year OS was 80, 92 and 39%, for low, intermediate and high-risk patients, respectively. Conclusions: OS was similar to that reported abroad, except for low risk patients, probably due to the low number of cases and short follow up. An improved survival should be expected with the routine use of immunochemotherapy.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.3 20192019-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300275es10.4067/S0034-98872019000300275 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Prognosis Treatment Outcome Waldenström Macroglobulinemia |
| spellingShingle |
Prognosis Treatment Outcome Waldenström Macroglobulinemia Cardemil,Daniela León,Pilar Peña,Camila Valladares,Ximena Cabrera,María Elena Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| description |
Background: Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein. Aim: To evaluate the clinical characteristics, management and results of treatment of patients with WM at a public hospital in Chile. Patients and Methods: Review of medical records of 31 patients aged 43 to 85 years (16 males) with WM diagnosed between 2002 and 2017. Clinical features and survival were recorded. Results: All patients had bone marrow compromise, and 31%, extranodal involvement. According to the International Prognostic Score System for WM (IPSSWM) 16, 58 and 26% were at low, intermediate and high risk, respectively. Twenty-five patients (81%) were treated, 32% with plasmapheresis and 36% with rituximab. Four cases (16%) achieved complete remission. Median follow up was 35 months (range 6-159). Estimated overall survival (OS) at 5 and 10 years was 74% and 53%, respectively. According to IPSSWM, the estimated five-year OS was 80, 92 and 39%, for low, intermediate and high-risk patients, respectively. Conclusions: OS was similar to that reported abroad, except for low risk patients, probably due to the low number of cases and short follow up. An improved survival should be expected with the routine use of immunochemotherapy. |
| author |
Cardemil,Daniela León,Pilar Peña,Camila Valladares,Ximena Cabrera,María Elena |
| author_facet |
Cardemil,Daniela León,Pilar Peña,Camila Valladares,Ximena Cabrera,María Elena |
| author_sort |
Cardemil,Daniela |
| title |
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| title_short |
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| title_full |
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| title_fullStr |
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| title_full_unstemmed |
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile |
| title_sort |
macroglobulinemia de waldenström. experiencia de 15 años en el hospital del salvador, santiago, chile |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2019 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300275 |
| work_keys_str_mv |
AT cardemildaniela macroglobulinemiadewaldenstromexperienciade15anosenelhospitaldelsalvadorsantiagochile AT leonpilar macroglobulinemiadewaldenstromexperienciade15anosenelhospitaldelsalvadorsantiagochile AT penacamila macroglobulinemiadewaldenstromexperienciade15anosenelhospitaldelsalvadorsantiagochile AT valladaresximena macroglobulinemiadewaldenstromexperienciade15anosenelhospitaldelsalvadorsantiagochile AT cabreramariaelena macroglobulinemiadewaldenstromexperienciade15anosenelhospitaldelsalvadorsantiagochile |
| _version_ |
1718437050636566528 |